Anti-VEGF /kg

PreclinicalSmall molecule

Anti-VEGF /kg is one of 6 small molecule programs targeting Stereotactic Body Radiotherapy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Stereotactic Body RadiotherapyRecruiting

Stereotactic Body RadiotherapyPreclinical

Recruiting

Competition

Competitive Landscape

5 competitors in Stereotactic Body Radiotherapy

#DrugCompanyPhaseTrials

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2

1 2

Tuoyi

SSun Yat-sen University

Phase 2

1 3

Keytruda

Merck & Co.

Phase 1

2 4

AZD1390

AstraZeneca

Phase 1

1 5

Anti-VEGF /kg

ZZhejiang Cancer Hospital

Preclinical

1 6

Oxaliplatin and Capecitabine

ZZhejiang Cancer Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Stereotactic Body Radiotherapy1 trial

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

Recruiting·ZZhejiang Cancer Hospital·N/A·NCT06349044·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Anti-VEGF /kg. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-VEGF /kg compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-VEGF /kg. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhejiang Cancer Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: ZZhejiang Cancer Hospital

Anti-VEGF /kg

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Stereotactic Body Radiotherapy1 trial

References

Drug Info

Quick Facts

Related News